Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Expands By 11.0%

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 62,800 shares, a growth of 11.0% from the March 15th total of 56,600 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average trading volume of 76,600 shares, the short-interest ratio is currently 0.8 days.

Hepion Pharmaceuticals Trading Down 1.8 %

Shares of HEPA opened at $2.19 on Monday. Hepion Pharmaceuticals has a fifty-two week low of $1.49 and a fifty-two week high of $20.66. The stock has a fifty day moving average of $2.30 and a two-hundred day moving average of $3.03.

Institutional Trading of Hepion Pharmaceuticals

Several institutional investors have recently made changes to their positions in HEPA. Renaissance Technologies LLC grew its stake in shares of Hepion Pharmaceuticals by 151.7% during the 1st quarter. Renaissance Technologies LLC now owns 126,600 shares of the company’s stock valued at $163,000 after buying an additional 76,300 shares during the period. State Street Corp grew its stake in shares of Hepion Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after buying an additional 26,194 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Hepion Pharmaceuticals by 45.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 87,541 shares of the company’s stock valued at $44,000 after buying an additional 27,487 shares during the period. BlackRock Inc. grew its stake in shares of Hepion Pharmaceuticals by 0.3% during the 1st quarter. BlackRock Inc. now owns 1,602,772 shares of the company’s stock valued at $1,245,000 after buying an additional 5,206 shares during the period. Finally, Armistice Capital LLC purchased a new stake in shares of Hepion Pharmaceuticals during the 3rd quarter valued at $1,984,000. 17.24% of the stock is owned by hedge funds and other institutional investors.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.